[{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","commit":"3b662d41c0","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for the last approved products without one","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Trastuzumab%20deruxtecan\" }]"}]},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"class"},{"field":"props"},{"field":"pairs"},{"field":"food"},{"field":"source"}]},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"tldr","before":"\"The most successful ADC ever. It redefined HER2 by working in tumours with only tiny amounts of the protein, and in 2026 moved into early-stage breast cancer.\"","after":"\"Trastuzumab deruxtecan (Enhertu) is the most successful ADC ever. It redefined HER2 by working in tumours with only tiny amounts of the protein, and in 2026 moved into early-stage breast cancer.\""}]}]